Accéder au contenu
Merck

HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.

Gut (2013-10-29)
Gi-Ae Kim, Young-Suk Lim, Jihyun An, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Han Chu Lee, Young-Hwa Chung, Yung Sang Lee, Dong Jin Suh
RÉSUMÉ

Little is known about the long-term clinical outcome and durability of HBsAg seroclearance following nucleos(t)ide analogue (NUC) therapy in patients with chronic hepatitis B (CHB). During a median follow-up period of 6 years (33 567 patient-years) of 5409 CHB patients who were initially treated with lamivudine or entecavir, a total of 110 achieved HBsAg seroclearance (0.33% annual seroclearance rate) and were included in this study. Baseline alanine aminotransferase (ALT) level >5 times of upper limit of normal was associated with higher probability of HBsAg seroclearance (HR 1.80, p<0.01), while HBeAg positivity (HR 0.46, p<0.01), high HBV DNA level (log(10) IU/mL; HR 0.61, p<0.01), and cirrhosis (HR 0.48, p<0.01) were inversely associated with the probability of HBsAg seroclearance by multivariable analysis. During follow-up for 287 patient-years after HBsAg seroclearance, only two patients with baseline cirrhosis developed hepatocellular carcinoma (HCC) or died (0.7% annual risk), which was of a significantly lower rate compared with propensity score-matched patients without HBsAg seroclearance (HR 0.09, p<0.01). HBsAg reversion and/or HBV DNA reversion occurred in 18 patients, most of which were transient with extremely low serum levels of HBsAg (0.05-1.00 IU/mL) and HBV DNA (17-1818 IU/mL). None required retreatment. The cumulative probability of anti-HBs seroconversion (detection of anti-HBs) at 4 years was 67.4% by Kaplan-Meier analysis. Selection for lamivudine-resistance HBV mutants during treatment was not associated with composite reversion (p=0.66). HBsAg seroclearance achieved after NUC treatment was associated with favourable clinical outcomes and was durable in most cases during long-term follow-up.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Guanine, 98%
Sigma-Aldrich
Guanine, BioUltra
Supelco
Guanine, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Lamivudine, ≥98% (HPLC), powder
Supelco
Lamivudine, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Lamivudine, United States Pharmacopeia (USP) Reference Standard
Lamivudine, European Pharmacopoeia (EP) Reference Standard
Lamivudine for system suitability 1, European Pharmacopoeia (EP) Reference Standard
Lamivudine for system suitability 2, European Pharmacopoeia (EP) Reference Standard